Jean-Jacques Bienaimé, BioMarin CEO (via YouTube)
October 7, 2022 07:25 AM EDT
People

Bio­Marin lays off 120 staffers to 'sim­pli­fy' the com­pa­ny while FDA re­views its big gene ther­a­py

Amber Tong

By the time the FDA hands down its de­ci­sion on val­rox, Bio­Marin will be a dif­fer­ent com­pa­ny — lit­er­al­ly.

The biotech is lay­ing off about 120 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times